AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05870800
Drug: Oxaliplatin injection 85mg/m2 + Leucovorin 400mg/m2 + 5-Fluorouracil 2400mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After Surgery, if patients are still considered at high risk (per treating investigator) subjects will be eligible to receive adjuvant chemotherapy with mFOLFOX6 Q2 weeks x 6 cycles (12 weeks) or CAPEOX Q3 weeks x 4 cycles (12 weeks)
Trial: NCT05870800
Drug: Oxaliplatin 130mg/m2 + Capecitabine 1000mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After Surgery, if patients are still considered at high risk (per treating investigator) subjects will be eligible to receive adjuvant chemotherapy with mFOLFOX6 Q2 weeks x 6 cycles (12 weeks) or CAPEOX Q3 weeks x 4 cycles (12 weeks)
Trial: NCT04848857
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: the placebo is a drug with no chemical effects but with the same physical characteristics as the experiment drug colchine.
Trial: NCT04915950
Drug: Temanogrel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a single oral dose of temanogrel during the treatment visit.
Trial: NCT04915950
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a single oral dose of temanogrel matching placebo during the treatment visit.
Trial: NCT04909879
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Excipient solution
Trial: NCT05737030
Drug: L-ornithine L-aspartate
RxNorm normalized name: L-ornithine L-aspartate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amino acid combination
Trial: NCT05594745
Drug: Systane Free
RxNorm normalized name: Systane Free
FDA approved: no
EMA approved: no
PMDA approved: no
Description: eyedrop
Trial: NCT05352633
Drug: Standard BP Arm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants in the Standard BP treatment group have a goal of SBP \<140 mmHg. The same medications used in the Intensive BP treatment group will be used for the Standard BP treatment group.
Trial: NCT05600777
Drug: BLU-5937
RxNorm normalized name: Blu-Kote
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration of BLU-5937 Tablets
Trial: NCT05600777
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration of matching placebo for BLU-5937 Tablets
Trial: NCT04843891
Drug: [64]Cu Macrin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Up to 15 mCi of \[68Ga\]CBP8 will be administered to each subject.
Trial: NCT04696952
Drug: TS-142
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TS-142
Trial: NCT04696952
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT05414734
Drug: HHT120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule, oral administration
Trial: NCT05414734
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule, oral administration
Trial: NCT06565897
Drug: Test regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: toothpaste \& manual toothbrush
Trial: NCT06565897
Drug: Control regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: toothpaste \& manual toothbrush
Trial: NCT05328531
Drug: Genakumab for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg/1ml/bottle
Trial: NCT05328531
Drug: Placebo for Genakumab for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo contains other excipients except Genakumab, and its appearance is consistent with that of Genakumab for injection
Trial: NCT04883333
Drug: LEO 153339
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: LEO 153339
Trial: NCT04883333
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT04895358
Drug: liposomal doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion
Trial: NCT04895358
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oral administration
Trial: NCT04895358
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion
Trial: NCT05970354
Drug: VersaPro Cream Base for Compounding
RxNorm normalized name: VersaPro Cream Base for Compounding
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT05145283
Drug: NaCl 0.9%)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline (NaCl 0.9%) will serve as placebo treatment. The respective amount of saline (according to patient weight matching the volume of conestat alfa that would have been used for this patient) will be withdrawn in an opaque syringe for slow IV injection.
Trial: NCT06533098
Drug: Intravenous immunoglobulins (IVIG)
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVIG will be administered intravenously.
Trial: NCT05391607
Drug: Hyperoncotic Albumin 20%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration during removal of the bladder (i.e. the bleeding part) of cystectomy procedures.
Trial: NCT05682222
Drug: EDP2939
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EDP2939 is a pharmaceutical preparation of extracellular vesicles.
Trial: NCT05682222
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo.
Trial: NCT05140824
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% sodium chloride solution
Trial: NCT04937452
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administration for 24 weeks
Trial: NCT00201552
Drug: Statin
RxNorm normalized name: Statin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT06067698
Drug: Mesalamine and Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mesalamine 1000 mg every 8 hrs. + Placebo once daily for 3 months
Trial: NCT06014515
Drug: 11C-butanol
RxNorm normalized name: BUTANOLS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each subject will undergo a dynamic 18F-FDG PET/CT scan (this drug is FDA approved) and a dynamic 11C-butanol PET/CT scan (this drug is under an IND) on the EXPLORER total-body PET/CT system. The two scans will be performed on the same day or within a period of up to two weeks depending on subject, imaging agent and scanner availability.
Trial: NCT04614233
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be randomly assigned to take 2 capsules of placebo daily for 16 months. Placebo capsules will consist of 180mg of hypromellose.
Trial: NCT06529185
Drug: pharmacological treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patient will receive the usually pharmacological treatment.
Trial: NCT05251779
Drug: Volatile Oil of Cang-Ai
RxNorm normalized name: Lantana camara leaf volatile oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The test group will be given Volatile oil of Cang-Ai (hereafter referred to as CAVO) for inhalation
Trial: NCT05849922
Drug: SAR442970
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mL extractable volume of 150 mg/mL SAR442970 filled in 2 mL glass vial
Trial: NCT05849922
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mL extractable volume of placebo filled in 2 mL glass vial
Trial: NCT05601531
Drug: Vit.D3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local administration of Vit.D3, through the effect of Vit.D3 to explore whether it can help to accelerate the healing of tooth extraction cavity and the clinical effectiveness of bone regeneration.
Trial: NCT04955678
Drug: Calcium, hydrolysed divinylbenzene-Me 2-fluoro-2-propenoate-1, 7-octadiene polymer sorbitol complexes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZG-801 is powder for suspension. In Run-in period, ZG-801 is taken once a day for 4 or 5 weeks. In Double-blind period, ZG-801 is taken once a day for 4 weeks.
Trial: NCT04955678
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is powder for suspension. In Double-blind period, Placebo is taken once a day for 4 weeks.
Trial: NCT04855201
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT05509192
Drug: Classic Induction
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients assigned to CI will be induced as per routine care using lidocaine 1 mg/kg, an opioid such a fentanyl (1-2 mcg/kg), propofol 1-2 mg/kg, and rocuronium 0.6 mg/kg, and the intubation will be performed with a C-MAC. Patients will also count down from one hundred. The medications used for induction of anesthesia in both arms of the study are those used for routine anesthesia care. In both study arms, dosing of medications for induction of anesthesia is standardized (lidocaine 1 mg/kg, fentanyl 1-2 mcg/kg, propofol 1-2 mg/kg, and rocuronium 0.6 mg/kg). The only difference between the two arms will be the timing of the medication administration, and the order in which medications are administered. The documentation of induction and intubation will be the same as that of the MTPI group. Vital signs and other parameters will continuously be recorded in the intraoperative record. Emergence and extubation are not protocolized.
Trial: NCT06300307
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for infusion
Trial: NCT05504876
Drug: HEC74647PA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered HEC74647PA 100 mg orally once daily in fed state;
Trial: NCT05504876
Drug: HEC110114
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered HEC110114 600 mg orally once daily in fed state;
Trial: NCT05630963
Drug: PET radiotracer
RxNorm normalized name: Pet Pectillin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A Nociceptin/Orphanin FQ (N/OFQ) peptide tracer (\[11C\] NOP-1A) will be used as the PET radiotracer. Approximately 10 mCi of this tracer will be delivered intravenously as a slow bolus over 60 seconds with beginning of the PET imaging acquisition. Approximately 60 ml of blood will be drawn from an artery throughout the dynamic PET acquisition in order to measure the blood N/OFQ levels.
Trial: NCT04633187
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects took EDP-938 matching placebo tablets once a day orally for 21 days
Trial: NCT05610813
Drug: VER-01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized oleoresin of Cannabis sativa L. folium cum flore, THC-chemotype (cannabis leaves and - flowers), corresponding to 21 mg (-)-trans-Δ9-Tetra-hydrocannabinol (THC) per gram drug product
Trial: NCT05610813
Drug: Opioid therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patient-specific selection of the marketed opioid (based on standard of care and provided for this study) is at the discretion of the investigator and made at Visit 1, i.e., before randomization at Visit 2.
Trial: NCT06023758
Drug: XELOX
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxaliplatin 130mg/m2 d1，Capecitabine 1000mg/m2 d1-14，Q3W
Trial: NCT05738681
Drug: N acetyl cysteine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N acetyl cysteine 1,200 mg/day for 8 weeks in NAC group
Trial: NCT04874311
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin will be administered by intravenous infusion on day 1 every 3 weeks at a fixed dose of 75 mg/m² for a maximum of 6 cycles
Trial: NCT04608539
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose infusion (placebo), postoperative day 1
Trial: NCT06102824
Drug: Organoid-guided treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The drugs predicted to be the most sensitive through organoid drug sensitivity screening. The drugs selected for sensitivity screening are from the following options: taxane, anthracycline, 5-fluorouracil, gemcitabine, vinorelbine, eribulin, utidelone, carboplatin, sacituzumab govitecan, and trastuzumab deruxtecan (for HER2-low patients).
Trial: NCT06102824
Drug: Taxane
RxNorm normalized name: Taxanes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albumin-bound paclitaxel 260mg/m2, IV, q3w, or 100-125mg/m2, IV, days 1, 8, and 15, q4w OR Liposomal paclitaxel 175mg/m2, IV, q3w
Trial: NCT06102824
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000-1250mg/m2, PO, bid, days1-14, q3w
Trial: NCT06102824
Drug: Anthracycline
RxNorm normalized name: Anthracycline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liposomal doxorubicin 50mg/m2, IV, q3w OR Liposomal doxorubicin 40mg/m2+Cyclophosphamide 600mg/m2, IV, q3w
Trial: NCT02422368
Drug: Methylprednisolone + ASTED
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ASTED tablet: Twice daily for 6 months~Methylprednisolone:~Methylprednisolone tablet of 50 and 5 mg, company....) 1mg/kg for the first 2 weeks, 0.8mg/kg for 2 weeks, 0.7 mg/kg for 2 weeks, and then tapering off the methylprednisolone in 6 weeks (total duration of 12 weeks) by 8-10 mg per week. For example, a patient with 75 kg weight will receive 75 mg for 2 weeks, 60 mg for 2 weeks, 52.5 mg for 2 weeks, and then decreasing by 8-10 mg per week for 6 weeks. The dose regiment will be written and handed to the patient on the first visit and will be monitored during the follow ups.
Trial: NCT02422368
Drug: Methylprednisolone +Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo: twice daily~Methylprednisolone:~Methylprednisolone tablet of 50 and 5 mg, company....) 1mg/kg for the first 2 weeks, 0.8mg/kg for 2 weeks, 0.7 mg/kg for 2 weeks, and then tapering off the methylprednisolone in 6 weeks (total duration of 12 weeks) by 8-10 mg per week. For example, a patient with 75 kg weight will receive 75 mg for 2 weeks, 60 mg for 2 weeks, 52.5 mg for 2 weeks, and then decreasing by 8-10 mg per week for 6 weeks. The dose regiment will be written and handed to the patient on the first visit and will be monitored during the follow ups.
Trial: NCT06410924
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching DD01
Trial: NCT06542445
Drug: Oral Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo oil that is similar in appearance and taste to the CBD oil. Titration and dosing identical to those described for the CBD oil.
Trial: NCT05897424
Drug: SAR447537
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A1PI, Recombinant, Bivalent Fc Fusion Protein
Trial: NCT04983589
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxymetazoline HCl and pilocarpine HCl placebo ocular drops.
Trial: NCT05797948
Drug: CD19/CD22 CAR-T
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Targets of CAR-T cells are tandem CD19/CD22. 1 \* 10 \^ 7/kg dual-target CAR-T cells were reinfused with 10%, 30% and 60% of the total dose on d1, d2, d3 respectively.
Trial: NCT05797948
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide 300mg/m2 ivgtt d3-d5.
Trial: NCT05838768
Drug: HRO761
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet
Trial: NCT05349760
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline/D5W
Trial: NCT05238701
Drug: LPM3770164 sustained release tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LPM3770164 sustained release tablet will be administrated orally single-dose on day 1
Trial: NCT05238701
Drug: LPM3770164 sustained release tablet simulant
RxNorm normalized name: STAPHYLOCOCCUS SIMULANS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LPM3770164 sustained release tablet simulant will be administrated orally single-dose on day 1
Trial: NCT06316843
Drug: Valacyclovir celecoxib dose 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1500 mg valacyclovir 200 mg celecoxib taken two times a day
Trial: NCT06316843
Drug: Valacyclovir celecoxib dose 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 750 mg valacyclovir 200 celecoxib mg taken two times a day
Trial: NCT06316843
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules colored matched to investigational product taken two times a day
Trial: NCT06136624
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Administered orally or IM as a rescue medication
Trial: NCT04718727
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral Placebo tablets one-hour preoperatively
Trial: NCT06041269
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT05451849
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide
Trial: NCT06566352
Drug: injection of epinephrine 1mg diluted in 200mg of NaCl
RxNorm normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: injection of epinephrine 1mg diluted in 200mg of NaCl
Trial: NCT05839548
Drug: Mepivacaine 2% with epinephrine 1:100,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local Anesthesia
Trial: NCT05839548
Drug: Articaine (4%) with epinephrine 1:100,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local Anesthesia
Trial: NCT06565871
Drug: HRS9531 Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Titration administration, SC
Trial: NCT06565871
Drug: Placebo Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SC
Trial: NCT05122598
Drug: Sham
RxNorm normalized name: SHAMPOO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham COT uses artificially scented compressed room air instead of olfactory stimulants and has control cognitive olfactory tasks.
Trial: NCT00137878
Drug: TNFerade™
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04356196
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral tablet
Trial: NCT05499130
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo
Trial: NCT05109416
Drug: Saline 0.9%
RxNorm normalized name: CVS Saline 0.9% Nasal Mist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic crystaloid
Trial: NCT04672954
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching to 10 mg BI 474121 administered as uncoated tablets with 240 milliliter of water after subjects fasted overnight for at least 10 hours. This arm was part of Part 1: randomised, placebo-controlled, single-blind.
Trial: NCT04672954
Drug: 2.5 milligram (mg) BI 474121
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg BI 474121 administered as uncoated tablets (1 x 2.5 mg) with 240 milliliter of water after subjects fasted overnight for at least 10 hours. This arm was part of Part 3 of the study: randomised, open-label.
Trial: NCT04672954
Drug: 20 milligram (mg) BI 474121
RxNorm normalized name: bis-isobutylene PPG-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg BI 474121 administered as uncoated tablets (2 x 10 mg) with 240 milliliter of water after subjects fasted overnight for at least 10 hours. This arm was part of Part 1 of the study: randomised, placebo-controlled, single-blind.
Trial: NCT05260658
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CFTX-1554 matching placebo
Trial: NCT05933265
Drug: Spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A competitive mineralocorticoid receptor antagonist that inhibits aldosterone-dependent sodium reabsorption/ potassium excretion and lowering blood pressure, as well as degrades the transcription coupled nucleotide excision repair protein ERCC3 to impair DNA repair.
Trial: NCT05131893
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: chemotherapy
Trial: NCT05131893
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: chemotherapy
Trial: NCT06455969
Drug: Testosterone gel (AndroGel 5g)
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Male subjects will be randomly assigned to receive a topical testosterone gel (5g dose).
Trial: NCT06455969
Drug: Testosterone gel (AndroGel 1.25g)
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Male subjects will be randomly assigned to receive a topical testosterone gel (1.25g dose).
Trial: NCT06455969
Drug: Estradiol / Levonorgestrel Transdermal System [Climara Pro]
RxNorm normalized name: estradiol / levonorgestrel Transdermal System [Climara Pro]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Female subjects will be randomly assigned to receive a estrogen/ progesterone patch.
Trial: NCT06455969
Drug: Placebo Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Female subjects will be randomly assigned to receive a placebo patch identical to the Climara Pro patch.
Trial: NCT05596227
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl will be injected during the induction of anesthesia (1-1.5 mg/kg)